NCX is an Important Determinant for Premature Ventricular Activity in a Drug-induced Model of Andersen-Tawil Syndrome
Overview
Affiliations
Aims: Andersen-Tawil syndrome (ATS1)-associated ventricular arrhythmias are initiated by premature ventricular activity (PVA) resulting from diastolic Ca(2+) (Ca(D)) accumulation. We hypothesized that relatively high Na(+)-Ca(2+) exchanger (NCX) expression coupled with slower Ca(2+) uptake may constitute an arrhythmogenic substrate during drug-induced ATS1 (DI-ATS1).
Methods And Results: DI-ATS1 was induced with 10 µmol/L BaCl(2) and 2 mmol/L [K(+)](o). Ca(2+) transients and action potentials were optically mapped from Langendorff-perfused guinea pig ventricles. Intracellular Ca(2+) handling was modulated by either direct NCX inhibition with 5 µmol/L KB-R7943 or by sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) inhibition with cyclopiazonic acid (CPA). During DI-ATS1, PVA was more frequent in left ventricular (LV)-base (LVB) vs. LV-apex (LVA) (2.2 ± 0.8 vs. 0.6 ± 0.3 PVA/10 min), consistent with greater Ca(D) (1.65 ± 0.13 vs. 1.42 ± 0.09 normalized-Ca(D) units) and western blot-assessed NCX protein expression (81.2 ± 30.9%) in LVB relative to LVA. Further, regions of high NCX (LVB) evidenced a shorter PVA coupling interval relative to regions of low NCX expression (LVA, 67.7 ± 3.5 vs. 78.5 ± 3.6%). Inhibiting NCX during DI-ATS1 lowered the incidence of ventricular tachycardias (VTs, 0 vs. 25%) and PVA (1.5 ± 0.4 vs. 4.3 ± 1.4 PVA/10 min), but it did not affect PVA coupling intervals in LVB nor LVA (70.8 ± 4.3 vs. 73.8 ± 2.5%). Conversely, inhibition of SERCA2a with CPA, thereby increasing the role of NCX in Ca(2+) handling, significantly increased the incidence of VTs and PVA relative to DI-ATS1 alone, while decreasing the PVA coupling interval in all regions.
Conclusion: PVA preferentially occurs in regions of enhanced NCX expression with relatively slower Ca(2+) uptake and during perfusion of CPA which further reduces sarcoplasmic reticular Ca(2+) uptake.
Munger M, Olgar Y, Koleske M, Struckman H, Mandrioli J, Lou Q J Am Heart Assoc. 2020; 9(11):e015119.
PMID: 32468902 PMC: 7429002. DOI: 10.1161/JAHA.119.015119.
Struckman H, Baine S, Thomas J, Mezache L, Mykytyn K, Gyorke S Microsc Microanal. 2020; 26(1):157-165.
PMID: 31931893 PMC: 7061261. DOI: 10.1017/S1431927619015289.
Cardiac Arrhythmias as Manifestations of Nanopathies: An Emerging View.
Radwanski P, Johnson C, Gyorke S, Veeraraghavan R Front Physiol. 2018; 9:1228.
PMID: 30233404 PMC: 6131669. DOI: 10.3389/fphys.2018.01228.
Koleske M, Bonilla I, Thomas J, Zaman N, Baine S, Knollmann B J Gen Physiol. 2018; 150(7):991-1002.
PMID: 29793933 PMC: 6028491. DOI: 10.1085/jgp.201711909.
Campana C, Akar F Front Bioeng Biotechnol. 2017; 5:59.
PMID: 29057224 PMC: 5635327. DOI: 10.3389/fbioe.2017.00059.